Medizone Intl. (fka MZEIQ)

[teq0904]

All those studies cost a lot of bucks and would require regulatory approval toxicity and efficacy studies as well as cost benefit - before any hospital would buy a new product - mzei doesn't have any cash for that. They have stuck with a finished product and what looked like the quickest pathway to sales, instead of going in different directions.
There are many competing technologies for wound care in the marketplace and on the sidelines trying to attract the attention of big bucks pharma companies to develop their products - not a simple subject for an investor to analyze - I know of a few on the sidelines going nowhere looking for cash, so there must be many more.